View Post

Therapeutic cancer vaccine shows promise against multiple tumor types

In In The News by Barbara Jacoby

By: Dennis Thompson From: medicalxpress.com Marc Baum went through all the usual steps to treat his bladder cancer—a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period. But doctors hope that an extra step—an experimental vaccine—will be what keeps Baum’s cancer from coming back. A vaccine that uses genetics to teach a person’s immune system how to …

View Post

Gedatolisib Plus Palbociclib Shows Promise in Treating ER+/HER2- Advanced Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer. Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib (Ibrance) and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer, according to early results on a …

View Post

New potential breast cancer drug identified

In In The News by Barbara Jacoby

By: PTI From: telanganatoday.com Scientists, including an Indian-American researcher, have identified a molecule that can help treat breast cancer, giving hope to patients who have become resistant to traditional therapies. The first-in-class molecule shuts down oestrogen-sensitive breast cancer in a new way, researchers said. First-in-class drugs are those that work by a unique mechanism – in this case a molecule …

View Post

Rare Patient Voice: Study Opportunity for Non-Small Cell Lung Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! …

View Post

First-Line Palbociclib/Letrozole Shows Real-World Survival Benefit in HR+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting. Palbociclib (Ibrance) in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor (HR)–positive, HER2-negative, metastatic …

View Post

500,000+ Trinity Health patients affected in widespread Accellion data breach

In In The News by Barbara Jacoby

By: Anuja Vaidya From: medcitynews.com Several healthcare entities that used Accellion’s file transfer software now find themselves the victims of a data breach, including Trinity Health. The software had vulnerabilities that were exploited by cybercriminals, resulting in the exposure of personal health information. A data breach resulting from vulnerabilities in file transfer service provider Accellion’s software has affected multiple healthcare …

View Post

Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Audrey Sternberg From: cancernetwork.com An analysis of real-world outcomes in a cohort of patients treated in mostly community settings showed that palbociclib plus letrozole improved both progression-free and overall survival in women with hormone receptor–positive, HER2-negative metastatic breast cancer. Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone …

View Post

Guidance Offered for Breast Implant Removal Without Replacement

In In The News by Barbara Jacoby

By: Marcia Frellick From: medscape.com More women with breast implants are asking for them to be removed without replacement, authors of a new guidance say, but the field has lacked formal guidelines on how to present the surgical options methodically and scientifically to patients. Neil Tanna, MD, MBA, associate program director of plastic surgery at Northwell Health in Great Neck, …

View Post

Savvy Cooperative: Paid Opportunity for People Aged 60+ with Metastatic Solid Tumor Cancer

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Requirements: Current diagnosis of metastatic cancer by a healthcare provider Proof of diagnosis will be required to participate Ages 60+ Fluent English speaker, but does not need to be the primary language U.S. resident Details: 120-minute focus group 15-minute survey From home Receive: $175 Link: https://gigs.savvy.coop/60-mets/?r=44951 Why Sign Up? Your experiences are so valuable and important to creating better …

View Post

Rare Patient Voice: Population-Based Paid Opportunity for Breast Cancer Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: Web-Assisted Phone Interviews plus video tasks Non-Caucasian 135 min for Patients 90 min for Caregivers Compensation $475 for patients $125 for caregivers Please sign up at the link below for more information or to see if you qualify. Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you …